#Sweden #AI Technology #Stockholm #Nevisense #SciBase

SciBase Announces Key Developments for Reverse Share Split

Date of Announcement: May 28, 2026

SciBase Holding AB, a prominent company in the field of dermatological technology, is taking significant steps to optimize its share structure through a reverse share split. This strategic move aims to enhance the company's market performance and streamline its stock trading.

Overview of the Reverse Share Split

On May 19, 2026, during the Annual General Meeting (AGM), SciBase's board of directors made a decision to consolidate shares, whereby every hundred existing shares will merge into one. This effort is expected to provide a more robust framework for the company's stock, enhancing investor confidence and aligning it with industry standards.

The specifics of the transaction include:

• - Last day of trading before the split: June 3, 2026.
• - First day of trading after the split: June 4, 2026.
• - Record date for the split: June 5, 2026.

This adjustment will lower the total number of shares outstanding from approximately 1.02 billion to 10.22 million, offering a new ISIN code beginning June 4, 2026.

How the Shareholders are Affected

As part of this reverse share split, existing shareholders will receive a reduced number of shares based on their holding on the record date. If a shareholder's total does not result in a complete new share (i.e. an even division by one hundred), the company will ensure they receive additional shares free of cost to round up their holdings. This automatic adjustment simplifies the process for all involved.

Shareholders will see their share value and quantity adjusted accordingly as of the first trading day post-split, ensuring they are not disadvantaged by the change. The move is anticipated to lead to an improvement in share price stability, reflecting the true value of the company's offerings and capabilities in the dermatology tech sector.

Implications for Warrants

Additionally, adjustments will be made to the terms of the warrants of series TO 2, which were announced in relation to a capital raise in April 2024. After the reverse share split, the subscription rights per warrant will be recalculated, establishing each warrant’s entitlement at 0.0109 shares with a new subscription price of SEK 38.00 per share.

The Strategy Behind the Move

With over two decades of research backing its innovative AI-based dermatology solutions, SciBase is committed to improving patient outcomes through early detection and prevention. By consolidating shares now, the board aims to fortify the company's position as a market leader and facilitate better strategic opportunities moving forward.

CEO Pia Renaudin emphasizes that the reverse share split is a proactive measure to minimize patient suffering and improve overall healthcare outcomes while also aiming to reduce healthcare costs. The company’s flagship product, Nevisense, exemplifies this dedication to innovation in skin health management.

Conclusion

As SciBase embarks on this critical transition, stakeholders are encouraged to stay informed and active in understanding how these changes will affect their investments. The reverse share split is not just a financial maneuver; it is part of a broader vision to leverage artificial intelligence in advancing dermatological diagnostics, ultimately enhancing life quality. This strategic move underlines SciBase's commitment to both its shareholders and the healthcare community.

For those interested in further developments and information, direct contact can be made through their certified adviser, DNB Carnegie Investment Bank AB.

For additional queries or updates, shareholders can reach out to CEO Pia Renaudin directly via email or phone, as detailed above. Stay tuned for more updates on this significant development at SciBase.